LinkedIn-button

Services

Vaccine
development
service

The bridge between discovery
and pilot-scale GMP biomanufacturing.
Intravacc offers a one-stop shop
for independent vaccine development,
from discovery to pilot production
to clinical studies.

LEARN MORE
LinkedIn-button

Discover
Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization of innovative vaccines against infectious diseases. With over 100 years of experience in vaccine development and optimization, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world.

LEARN MOREANNUAL REPORT 2020
LinkedIn-button

Latest News

Intravacc launches hybrid business model to drive innovation and growth

Intravacc launches hybrid business model to drive innovation and growth Bilthoven, the Netherlands, 16 September 2021 – Intravacc, a global leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, today launches its new hybrid…

  • Hybrid model: CDMO services and development of a proprietary vaccine pipeline
  • Intravacc will also put emphasis on the therapeutic vaccine market
  • Intravacc’s proprietary vaccine portfolio will mainly focus on intranasal administration
  • Intravacc launches promotional campaign, supporting the funding of a phase I clinical trial with the Avacc 10 nasal spray vaccine
Read more

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the…

  • Sabin-IPV polio vaccine developed by Intravacc contributes to the eradication of polio
  • Sinovac’s polio vaccine (sIPV) receives market authorization from the NMPA in China
  • Intravacc’s cell technology also used for the development of Sinovac’s Covid-19 vaccine that was introduced on the market recently and is currently under rolling review by EMA
Read more

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme…

  • Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
  • Two conventional vaccines based on Intravacc's OMV platform and VEO cell platform
Read more
LinkedIn-button

Career

Join our team!

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

YOUR CAREER?

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.